Recent advancements in cancer treatment have emerged from over a decade of research led by scientists at the University of California, San Francisco (UCSF). The focus of this research has been on improving existing radiation therapies through innovative targeting of the KRAS protein, a key driver of tumor growth. KRAS mutations are found in nearly one-third of all cancers, particularly in lung, pancreatic, and colon cancers.
In 2013, researcher Kevan Shokat pioneered a drug that specifically targets the mutated form of KRAS. However, initial findings revealed that while the drug could inhibit tumor growth, it did not effectively eliminate the cancer cells, leading to potential recurrences. This sparked further investigation into how the drug could be utilized more effectively.
Recent studies have introduced a novel approach where the FDA-approved drug sotorasib is used to tag KRAS-containing tumors. This is coupled with a radioactive antibody designed to identify and bind to these tagged tumors. This method aims to deliver a targeted radiation dose, minimizing damage to surrounding healthy tissues. The researchers believe this “one-two punch” could significantly enhance the effectiveness of radiation therapy by not only attacking the tumors but also reducing the likelihood of resistance development.
The radioactive component of the antibody comes from zirconium-89, a substance already utilized in medical imaging techniques like Positron Emission Tomography (PET) scans. As research progresses, the next steps will involve developing specific antibodies that can respond to individual patient profiles, potentially allowing for broader implementation of this treatment in clinical settings. This innovative approach exemplifies the ongoing evolution of cancer therapies, focusing on precision and patient safety.